XPH vs. BMY
Compare and contrast key facts about SPDR S&P Pharmaceuticals ETF (XPH) and Bristol-Myers Squibb Company (BMY).
XPH is a passively managed fund by State Street that tracks the performance of the S&P Pharmaceuticals Select Industry Index. It was launched on Jun 19, 2006.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: XPH or BMY.
Correlation
The correlation between XPH and BMY is 0.45, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
XPH vs. BMY - Performance Comparison
Key characteristics
XPH:
-0.02
BMY:
0.42
XPH:
0.17
BMY:
0.83
XPH:
1.02
BMY:
1.10
XPH:
0.01
BMY:
0.25
XPH:
0.06
BMY:
1.54
XPH:
7.81%
BMY:
7.80%
XPH:
21.02%
BMY:
30.47%
XPH:
-48.03%
BMY:
-70.62%
XPH:
-29.69%
BMY:
-35.75%
Returns By Period
In the year-to-date period, XPH achieves a -6.26% return, which is significantly higher than BMY's -15.29% return. Over the past 10 years, XPH has underperformed BMY with an annualized return of -2.49%, while BMY has yielded a comparatively higher -0.53% annualized return.
XPH
-6.26%
9.07%
-15.10%
-0.37%
0.42%
-2.49%
BMY
-15.29%
-11.66%
-12.43%
12.63%
-1.61%
-0.53%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
XPH vs. BMY — Risk-Adjusted Performance Rank
XPH
BMY
XPH vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Pharmaceuticals ETF (XPH) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
XPH vs. BMY - Dividend Comparison
XPH's dividend yield for the trailing twelve months is around 1.64%, less than BMY's 5.20% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
XPH SPDR S&P Pharmaceuticals ETF | 1.64% | 1.58% | 1.28% | 1.64% | 0.95% | 0.47% | 0.64% | 0.65% | 0.67% | 0.63% | 7.15% | 5.55% |
BMY Bristol-Myers Squibb Company | 5.20% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% |
Drawdowns
XPH vs. BMY - Drawdown Comparison
The maximum XPH drawdown since its inception was -48.03%, smaller than the maximum BMY drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for XPH and BMY. For additional features, visit the drawdowns tool.
Volatility
XPH vs. BMY - Volatility Comparison
SPDR S&P Pharmaceuticals ETF (XPH) has a higher volatility of 10.99% compared to Bristol-Myers Squibb Company (BMY) at 10.24%. This indicates that XPH's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.